EU to consider medtech incentives to address rare diseases
This article was originally published in SRA
Executive Summary
The European Commission plans to assess whether legislative measures are needed to encourage the development of medical technology for rare diseases. In a communication outlining its strategy for improving the diagnosis and treatment of rare diseases, the commission notes that, unlike in the pharmaceutical area, there is currently no policy for medical devices in this field1.
You may also be interested in...
Stakeholders Deliberate on Developing US Social Media Guidance
Jeanette Marchant reports on discussions at the US Food and Drug Administration public hearing on how drug and medical device companies should use the internet and social media to promote regulated products.
Stakeholders Deliberate on Developing US Social Media Guidance
Jeanette Marchant reports on discussions at the US Food and Drug Administration public hearing on how drug and medical device companies should use the internet and social media to promote regulated products.
Asian group identifies criteria for device nomenclature system
The Asian Harmonization Working Party agreed six criteria for a medical device nomenclature system at its 14th meeting in Hong Kong on 4-7 November 20091. The requirements ? which will help in the selection of a nomenclature system service provider ? cover charges for using the system; its governance; ownership of the database; response times to requests; the system’s future development; and further use.